Intratumoral heterogeneity as a confounding factor in clonogenic assays for tumour radioresponsiveness.
The level of intra-tumoral heterogeneity of cellular radiosensitivity within primary cultures of three carcinomas of the cervix has been established. All three cultures contained clones that varied by as much as 3-fold in their clinically relevant radiosensitivity (SF2). The level of intra-tumoral heterogeneity observed in these cervical tumour cultures was sufficient to be a major confounding factor to the use of pre-treatment assessments of radiosensitivity to predict for clinical radioresponsiveness. Mathematical modeling of the relative elimination of the tumour clones during fractionated radiotherapy indicates that, in two of the three biopsy samples, the use of pre-treatment derived SF2 values from the heterogeneous tumour sample would significantly overestimate radioresponsiveness. We conclude that assays of cellular radiosensitivity that identify the radiosensitivity of the most radioresistant clones and measure their relative abundance could potentially increase the effectiveness of SF2 values as a predictive marker of radioresponsiveness.
Britten
R A
RA
Department of Experimental Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada. RichardB@CancerBoard.ab.ca
Evans
A J
AJ
Allalunis-Turner
M J
MJ
Franko
A J
AJ
Pearcey
R G
RG
D001706:Biopsy; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy*; D002455:Cell Division / Q000528:radiation effects; D005260:Female; D006801:Humans; D008962:Models, Theoretical; D011379:Prognosis; D011836:Radiation Tolerance / Q000502:physiology*; D011879:Radiotherapy Dosage; D011897:Random Allocation; D014407:Tumor Cells, Cultured; D014410:Tumor Stem Cell Assay / Q000379:methods*; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy*